• Mashup Score: 5
    Management of CNS Lymphoma | Blood Cancer Talks | Episode 32 - 1 year(s) ago

    In this episode, we discuss the management of primary CNS lymphoma, secondary CNS lymphoma and CNS prophylaxis with Dr. Kate Cwynarski. Here are the shownotes: 1. ASH 2022 data on PET scan in CNS lymphoma -…

    Source: share.transistor.fm
    Categories: Latest Headlines, Partners & KOLs
    Tweet Tweets with this article
    • Profile photo of BloodCancerTalk
      BloodCancerTalk

      Tune in to our new episode on management of CNS lymphoma with @CwynKate. We discuss primary & secondary CNS lymphoma as well as the contentious topic of CNS prophylaxis! https://t.co/V3yhzMvu4b #lymsm #bmtsm Check out this clip on cytarabine dose modification in CNS lymphoma: https://t.co/OG1vIylS5V

  • Mashup Score: 9
    Episode 30. Management of High-Risk Myeloma | Blood Cancer Talks | Episode 31 - 1 year(s) ago

    In this episode, we discuss with Dr. Martin Kaiser how to identify and manage newly diagnosed high-risk multiple myeloma in the current era of effective frontline therapies.  Here are the key studies that we touched upon:1. Phase II OPTIMUM (MUKnine) trial in ultra-high-risk myeloma and…

    Source: share.transistor.fm
    Categories: Latest Headlines, Partners & KOLs
    Tweet Tweets with this article
    • Profile photo of BloodCancerTalk
      BloodCancerTalk

      Our new episode on High-Risk #Myeloma just dropped! Tune is for @MyMKaiser take on the following- What is truly "high-risk"? What to make of +1q? What did we learn from OPTIMUM trial? How imp is GEP for defining high-risk? https://t.co/pBjNqvJ3YH https://t.co/atjImOEL4p

  • Mashup Score: 4
    Introduction to BloodCancerTalks - 1 year(s) ago

    Transistor (https://transistor.fm) https://feeds.transistor.fm/bloodcancertalks This is a podcast on latest advances in the understanding and management of blood cancers. Here, we will bring a wide range of experts within hematologic malignancies to discuss various topics in depth. Host: Raj Chakraborty, MD from Columbia University, New York, Ashwin Kishtagari, MD, from Vanderbilt University, Nashville, and Edward Cliff, MD, from Harvard University, Boston Tweet your suggestions and feedback to @rajshekharu

    Source: feeds.transistor.fm
    Categories: Latest Headlines, Partners & KOLs
    Tweet Tweets with this article
    • Profile photo of BloodCancerTalk
      BloodCancerTalk

      At @bloodcancertalks, we are committed to bringing fiercely independent and nuanced coverage of latest advances in hematologic malignancies in a "𝐇𝐨𝐰 𝐈 𝐓𝐫𝐞𝐚𝐭" format from thought leaders in the field! Check out our episodes➡️https://t.co/0QghqgcD9D! https://t.co/d8aj671oPK

  • Mashup Score: 2
    Episode 28. Management of CCUS - 2 year(s) ago

    Listen to this episode from Blood Cancer Talks on Spotify. In this episode, we discuss the diagnosis and management/monitoring of Clonal Cytopenias of Unknown Significance (CCUS) with Dr. Uma Borate. We also discuss the emerging data on risk stratification and key trials in this space that are currently ongoing. Here are the shownotes:1. CCUS and risk of transformation to myeloid neoplasms:https://www.sciencedirect.com/science/article/pii/S0006497121013471 2. Prediction of risk for myeloid neoplasms in clonal hematopoiesis:https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200310 3. CHRS risk score:http://www.chrsapp.com 4. Germline predisposition to clonal hematopoiesis: https://www.sciencedirect.com/science/article/abs/pii/S0145212623006094?via%3Dihubhttps://www.nature.com/articles/s41586-020-2819-2 5. Cancer therapy shapes the fitness landscape of clonal hematopoiesis:https://www.nature.com/articles/s41588-020-00710-0 6. Canakinumab for the prevention of progression to cancer in pati

    Source: open.spotify.com
    Categories: Latest Headlines, Partners & KOLs
    Tweet Tweets with this article
    • Profile photo of BloodCancerTalk
      BloodCancerTalk

      Tune in Ep 28 @BloodCancerTalk where we delve into the management of #CCUS with @beatalleukemia. We covered various intricacies involved in diagnosing and monitoring patients with #CCUS, as well as exciting ongoing clinical trials in this field! https://t.co/HRYcRbPb2C

Load More